This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

New clinical trial aims to tackle bowel cancer

Oxford University Hospitals has started a clinical trial which combines the use of immunotherapy with a protein-inhibiting drug for use with difficult-to-treat bowel cancer.

Immunotherapy combined with checkpoint inhibitor drugs has been used successfully as treatment for  several cancers, including melanoma and lung cancer, but until now has not worked so effectively on bowel cancer.

This study will test the combination of immunotherapy with binimetinib, which inhibits the protein MEK (mitogen-activated protein kinase kinase), which is often activated in bowel cancer.

For the full story on the Oxford Biomedical Research Centre website